Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma

Inclusion Criteria:

* able to understand and voluntarily sign an informed consent form
* able to adhere to the study visit schedule and other protocol requirements.
* age ≥ 65 years.
* life expectancy \> 6 months.Patients must have Symptomatic Measurable previously Untreated MM
* have measurable disease as defined by the following: quantifiable monoclonal M-component value in the serum and/or urine
* eastern Cooperative Oncology Group performance status score ≤2
* dequate bone marrow function, documented within 72 hours and without transfusion 5 days prior to the first intake of investigational product no growth factor support Adequate organ function
* subjects affiliated with an appropriate social security system.
* male subjects must:Understand the potential teratogenic,and genotoxic risk of Melphalan if engaged in sexual activity with a pregnant female or a female of childbearing potential.
* understand the potential genotoxic risk of Carfilzomib if engaged in sexual activity with a pregnant female or a female of childbearing potential.
* practice complete abstinence or understand the need and agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential throughout the entire duration of study treatment, during dose interruptions and until at least 3 months after the end of treatment discontinuation of CMP, even if he has undergone a successful vasectomy.
* if pregnancy or a positive pregnancy test does occur in the partner of a male study patient during study participation, the investigator must be notified immediately.
* agree not to donate semen or sperm during study drug therapy and until at least 3 months after the end of treatment discontinuation of CMP.

Exclusion Criteria:

* any other uncontrolled medical condition or comorbidity that might interfere with subject's participation.
* known positive for HIV or active infectious hepatitis, type B or C.
* patient with terminal renal failure that require dialysis and clearance creatinine \< 30 ml/min.
* prior history of malignancies, other than multiple myeloma, unless the patients has been free of the disease for ≥ 5 years.
* prior local irradiation within two weeks before first dose
* evidence of central nervous system (CNS) involvement.
* unable to take corticotherapy at study entry
* any ongoing adverse event or medical history \> grade 2 severity
* persons protected by a legal regime (guardianship, trusteeship).Alkeran's (Melphalan) contraindication: Hypersensitivity to Melphalan or to any other constituents.
* patients with heart failure class 3 and 4 according to the NYHA criteria, or patients with past history of myocardial infarction within the last 6 months or no controlled cardiac conduction abnormalities.
* patients with a left ventricular ejection fraction under or equal to 45 % (LVEF ≤ 45%)